The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
-
REGULATORY Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
-
REGULATORY MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
-
BUSINESS AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
-
REGULATORY MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
-
BUSINESS Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
-
REGULATORY MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
-
BUSINESS Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
-
REGULATORY Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
-
BUSINESS Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
-
REGULATORY Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
-
BUSINESS Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
-
BUSINESS Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
-
BUSINESS 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
-
BUSINESS Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
-
BUSINESS Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
-
ORGANIZATION Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
-
BUSINESS AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
-
REGULATORY MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
-
BUSINESS Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…